Retatrutide
Highest phase reached
Phase 3
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Protein
- Drug name
- Retatrutide
- ly 3437943
- LY-3437943
- ly3437943
- LY3437943
- retatrutide
- Retatrutide
- Retatrutide (LY3437943)
- retatrutide [INN]
- RETATRUTIDE [USAN]
- Retatrutide [WHO-DD]
- retatrutide inn
- retatrutide usan
- retatrutide who dd
- CAS registry numbers
- 2381089-83-2
- ChEMBL ID
- CHEMBL5095485
- RxNorm IDs (RxCUI)
- 2722410
- FDA ingredient codes (UNII)
- NOP2Y096GV
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- retatrutide
- Type
- Peptide
- Drug name stem
- -tide
- Mechanism
- Gastric inhibitory polypeptide receptor agonist
- Action type
- Agonist
- Target
- Gastric inhibitory polypeptide receptor
- Protein identifier
- P48546
- Mechanism
- Glucagon receptor agonist
- Action type
- Agonist
- Target
- Glucagon receptor
- Protein identifier
- P47871
- Mechanism
- Glucagon-like peptide 1 receptor agonist
- Action type
- Agonist
- Target
- Glucagon-like peptide 1 receptor
- Protein identifier
- P43220
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- GLP-1 receptor
- Gene symbol
- GLP1R
- Protein identifier
- P43220
- Median affinity
- 8.14
- Affinity units
- pKi
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- glucagon receptor
- Gene symbol
- GCGR
- Protein identifier
- P47871
- Median affinity
- 8.25
- Affinity units
- pKi
- Action
- Full agonist
- Action type
- FULL_AGONIST
- Target
- GIP receptor
- Gene symbol
- GIPR
- Protein identifier
- P48546
- Median affinity
- 10.24
- Affinity units
- pKi
- Mechanism
- Gastric inhibitory polypeptide receptor agonist
- Action type
- Agonist
- Target
- Gastric inhibitory polypeptide receptor
- Mechanism
- Glucagon receptor agonist
- Action type
- Agonist
- Target
- Glucagon receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
- Action type
- Agonist
- Target
- Glucagon-like peptide 1 receptor
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Obesity
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Renal Insufficiency
- Highest recorded phase
- 1
- Condition identifier
- HP:0000083
- Subject identifier
- D051437
- Condition
- Diabetes Mellitus, Type 2
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0005148
- Subject identifier
- D003924
- Condition identifier
- EFO_0000400
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 3
- Condition identifier
- HP_0000083
- Highest recorded phase
- 1
- Condition identifier
- HP_0001399
- Highest recorded phase
- 1
- Condition identifier
- HP_0001513
- Highest recorded phase
- 3
- Condition identifier
- HP_0001943
- Highest recorded phase
- 1
- Condition identifier
- HP_0025502
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004995
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005015
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005178
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005300
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0011122
- Highest recorded phase
- 3
- NCT04143802
- NCT04823208
- NCT04867785
- NCT06260722
- NCT06297603
- NCT04881760
- NCT05445232
- NCT05548231
- NCT06039826
- NCT06383390
- NCT05611957
- NCT06354660
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Sequence
- Type
- Protein
- Sequence
- YA1QGTFTSDYSIL2LDKK4AQA1AFIEYLLEGGPSSGAPPPS3
- Component
- Modified residues
- Sequence
- A1(SMILES):CNC(C)(C)C(C)=O
Related records
Trials (34)
- A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices
- A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants
- A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male Participants
- A Study of LY3437943 in Chinese Participants With Obesity Or Overweight
- A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function
- A Study of LY3437943 in Healthy Participants With a High Body Mass Index
- A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)
- A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
- A Study of LY3437943 in Participants With Impaired and Normal Liver Function
- A Study of LY3437943 in Participants With Type 2 Diabetes
- A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
- A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese
- A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight
- A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
- A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
- A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
- A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
In development for (4)
- Diabetes mellitus Phase 3
- Kidney failure Phase 1
- Obesity disorder Phase 3
- Type 2 diabetes mellitus Phase 3